Wednesday, 08 April, 2009 | Supplied by: Merck Pty Ltd

Novagen has introduced multiplex immunoassays for the bead-based Luminex xMAP Technology platform. The range of immuno-assays allows the multiplex quantification of phosphorylated proteins, giving researchers the opportunity to examine changes in cellular signalling that reflect disease states or various drug treatments.

The WideScreen EpiTag assays detect key signalling events in the ERK pathway from both human and mouse samples.

WideScreen RTK assays allow the simultaneous determination of tyrosine phosphorylation status of several key receptor tyrosine kinases.

The WideScreen Human Cancer Panel 1 provides the quantitative detection of six cancer-associated proteins found in biological fluids.

The WideScreen Human Cancer Panel provides quantitative detection of 12 human growth factors found in biological fluids.

The WideScreen Human Cardiovascular Disease Panel 1 provides quantitative detection of seven human apolipoproteins.

Finally, the WideScreen Human Cardiovascular Disease Panel 2 provides quantitative detection of six human cytokines/chemokines associated with cardiovascular disease.

Phone: 1800 335 571
Related Products

Enzo Life Sciences SARS-CoV-2 IgG ELISA kit

Enzo's ELISA assay is a qualitative assay optimised to provide sensitive detection of IgG...

GeneCopoeia ACE2 and lung stable cell lines for COVID-19 research

GeneCopoeia offers collections of cell lines expressing human host factors needed for SARS-CoV-2...

Greiner Bio-One cell culture microplates

Greiner Bio-One has various microplates available, including tissue culture microplates, with a...

  • All content Copyright © 2020 Westwick-Farrow Pty Ltd